Genentech Inc
Case Study of Genentech Inc.
Company Background
Genentech is considered as the founder of the bio-technology industry. It has been delivering on the promise of biotechnology for almost 30 years, using human genetic information to discover, develop, commercialize and manufacture bio-therapeutics that address significant unmet medical needs. It was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer.
Genentech is among the world’s leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions and over 40 projects in the pipeline.
The company, a member of the Roche Group, has headquarters in South San Francisco, California. Roche Holdings, Inc. owns Genentech approximately by 56 precent of outstanding shares on March, 2009.
Genentech’s five focus areas are Oncology, Immunology, Metabolism, Neuroscience, and Infectious Disease. Genentech markets its drugs globally including Europe, Canada, Japan and others. It also sells through hospitals and major medical centres, specialist physician in private practice, wholesalers.
Genentech, Inc. as a biotech company, it hold more than 40 drugs in its product pipeline and it generated product sales in 2008 worth $10.53 billion, an increase of 12% from $9.44 billion in 2007. Share price as of March 2009 was $94.97 per share. With total operation revenue of $13.42 billion in 2008, an increase of 14% occurred from $11.72 billion in 2007. Product sales in 2008 were $10.53 billion, an increase of 12% from $9.44 billion in 2007.
Company’s net income in 2008 was $3.43 billion and $2.77 billion in 2007. There was an increase of 24% from 2007 to 2008.Overall marketing, general and administrative (MG&A) expenses increased 7% to $2,405 million in 2008 and 12% to $2,256 million in 2007.
Royalty revenue increased 28% to $2,539 million in 2008 and 47% to $1,984 million in 2007. The increases were due to higher sales by Roche of Herceptin,
Company Background
Genentech is considered as the founder of the bio-technology industry. It has been delivering on the promise of biotechnology for almost 30 years, using human genetic information to discover, develop, commercialize and manufacture bio-therapeutics that address significant unmet medical needs. It was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer.
Genentech is among the world’s leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions and over 40 projects in the pipeline.
The company, a member of the Roche Group, has headquarters in South San Francisco, California. Roche Holdings, Inc. owns Genentech approximately by 56 precent of outstanding shares on March, 2009.
Genentech’s five focus areas are Oncology, Immunology, Metabolism, Neuroscience, and Infectious Disease. Genentech markets its drugs globally including Europe, Canada, Japan and others. It also sells through hospitals and major medical centres, specialist physician in private practice, wholesalers.
Genentech, Inc. as a biotech company, it hold more than 40 drugs in its product pipeline and it generated product sales in 2008 worth $10.53 billion, an increase of 12% from $9.44 billion in 2007. Share price as of March 2009 was $94.97 per share. With total operation revenue of $13.42 billion in 2008, an increase of 14% occurred from $11.72 billion in 2007. Product sales in 2008 were $10.53 billion, an increase of 12% from $9.44 billion in 2007.
Company’s net income in 2008 was $3.43 billion and $2.77 billion in 2007. There was an increase of 24% from 2007 to 2008.Overall marketing, general and administrative (MG&A) expenses increased 7% to $2,405 million in 2008 and 12% to $2,256 million in 2007.
Royalty revenue increased 28% to $2,539 million in 2008 and 47% to $1,984 million in 2007. The increases were due to higher sales by Roche of Herceptin,